Area of research
Hematology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Imatinib and Oncology, with related work in Myeloid leukemia, Hypotaurine, Monkeypox. Notable publications include 'Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling', 'A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy', and 'Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center...'.
Beyond proofreading: POLD1 mutations as dynamic orchestrators of genomic instability and immune evasion in cancer
USP35 promotes hepatocellular carcinoma proliferation through GASC1-mediated ROCK2 upregulation
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
Current status of PD-(L)1 inhibitor usage in advanced or metastatic non-small cell lung cancer: A national survey of oncologists in China.
Validation of the imatinib-therapy failure model
Epidemiology-based analysis of the risks and elimination strategies of the monkeypox outbreak in 2022
Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling